TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38533943

Group type: EXPERIMENTAL
Intervention: SCAD-induced PTSD symptoms
Number of subjects: 859

Group type: COMPARATOR
Intervention: Lifetime probable SCAD-induced PTSD diagnoses
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Past-month PTSD symptom severity
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Past-month SCAD-induced PTSD symptoms
Number of subjects: 859
Study: 38533953

Group type: EXPERIMENTAL
Intervention: Externally developed CAD polygenic risk score (PRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol PRS
Number of subjects: 0
Study: 38533961

Group type: EXPERIMENTAL
Intervention: Sildenafil (selective phosphodiesterase-5 inhibition)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 38533985

Group type: EXPERIMENTAL
Intervention: TNF inhibitors (TNFi)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No TNF inhibitors (Control)
Number of subjects: 158
Study: 38533983

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 4094

Group type: COMPARATOR
Intervention: COPD presence
Number of subjects: 4094

Group type: COMPARATOR
Intervention: Primary composite outcome
Number of subjects: 4094
Study: 38534105

Group type: EXPERIMENTAL
Intervention: Cardiac biofeedback
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 481

Group type: COMPARATOR
Intervention: Control
Number of subjects: 481
Study: 38534162

Group type: EXPERIMENTAL
Intervention: adherence-linked
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: clinic-linked
Number of subjects: 329

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 329
Study: 38534892

Group type: EXPERIMENTAL
Intervention: Simulation-based learning module
Number of subjects: 34

Group type: COMPARATOR
Intervention: Self-learning video
Number of subjects: 34
Study: 38535011

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) assessment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-dose non-contrast thoracic CT
Number of subjects: 30
Study: 38535039

Group type: EXPERIMENTAL
Intervention: Telemonitoring platform using a specialized smartphone application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard follow-up approaches (Control)
Number of subjects: 0
Study: 38535409

Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 1991

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 1991
Study: 38536017

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 38536082

Group type: EXPERIMENTAL
Intervention: Enzalutamide (120 mg/d) + Relacorilant (escalating doses, RP2D of 150 mg/d)
Number of subjects: 35
Study: 38536106

Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38536128

Group type: EXPERIMENTAL
Intervention: 3 g/day nicotinamide
Number of subjects: 1300
Study: 38536165

Group type: EXPERIMENTAL
Intervention: High-Dimensional Mass Cytometry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38536177

Group type: EXPERIMENTAL
Intervention: Sitting reduction intervention (10 health coaching contacts, sitting reduction goals, standing desk, fitness tracker)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Sitting reduction intervention
Number of subjects: 283

Group type: COMPARATOR
Intervention: Healthy living attention control (10 health coaching contacts to set general healthy living goals)
Number of subjects: 283
Study: 38536225

Group type: EXPERIMENTAL
Intervention: Minder mobile app
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1489
Study: 38536227

Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) HIV antiretroviral therapy (ART)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patient-oriented tools for comparing LAI ART and daily oral ART options
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Implementation outcomes measured through provider interviews, surveys, and service reporting
Number of subjects: 200
Study: 38536442

Group type: EXPERIMENTAL
Intervention: HEV-239 (Hecolin) vaccine, 30 µg administered intramuscularly on days 1, 29, and 180
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HEV-239 (Hecolin) vaccine, 30 µg administered intramuscularly
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HEV-239 (Hecolin) vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 38536534

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Number of subjects: 318

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Baseline hyperlactatemia
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Lactate levels during ICU stay
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Decrease in lactate levels from day one to seven in patients with baseline hyperlactatemia
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Secondary increase in lactate
Number of subjects: 318
Study: 38536545

Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation for 48 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous intravenous sedation (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation
Number of subjects: 60
Study: 38536592

Group type: EXPERIMENTAL
Intervention: Short-stitch technique
Number of subjects: 414

Group type: COMPARATOR
Intervention: Long-stitch technique
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 414
Study: 38536701

Group type: EXPERIMENTAL
Intervention: High resolution manometry (HRM) with Milan Score
Number of subjects: 295
Study: 38536764

Group type: EXPERIMENTAL
Intervention: Overminus spectacles (-2.50 D for 12 months, -1.25 D for 3 months, and nonoverminus for 3 months)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Nonoverminus spectacles
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Overminus spectacles
Number of subjects: 386
Study: 38536810

Group type: EXPERIMENTAL
Intervention: Monthly intravenous infusion of dual bNAbs (VRCO1LS and 10-1074)
Number of subjects: 25
Study: 38536852

Group type: EXPERIMENTAL
Intervention: NoObesity app
Number of subjects: 35
Study: 38536994

Group type: EXPERIMENTAL
Intervention: intra-mucosal injection of injectable platelet-rich fibrin (i-PRF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: no treatment (Control)
Number of subjects: 10
Study: 38536997

Group type: EXPERIMENTAL
Intervention: Advance Directive document
Number of subjects: 120
Study: 38537027

Group type: EXPERIMENTAL
Intervention: Home-based exercise delivery mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gym-based exercise delivery mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 0
Study: 38537053

Group type: EXPERIMENTAL
Intervention: M1-rTMS with naloxone
Number of subjects: 45

Group type: COMPARATOR
Intervention: M1-rTMS with saline
Number of subjects: 45

Group type: COMPARATOR
Intervention: DLPFC-rTMS with saline
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: M1-rTMS or DLPFC-rTMS
Number of subjects: 45
Study: 38537155

Group type: EXPERIMENTAL
Intervention: Giredestrant (30 mg oral once daily)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Physician's choice of endocrine monotherapy (PCET)
Number of subjects: 303
Study: 38537251

Group type: EXPERIMENTAL
Intervention: Peanut-based whole foods/snacks (PNT group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-carbohydrate, peanut-free snack (CHO group)
Number of subjects: 32
Study: 38537255

Group type: EXPERIMENTAL
Intervention: Adjuvanted 3.75 μg + AS03/2017 doses with delayed boost interval
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Two doses of A(H7N9) IIV
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Adjuvanted second dose with longer interval
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: AS03 adjuvant with second H7N9 IIV dose and extended boost interval to 4 months
Number of subjects: 180
Study: 38537270

Group type: COMPARATOR
Intervention: Whey protein (32 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plant protein blend (32 g)
Number of subjects: 10
Study: 38537315

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD1) administered intravenously until end of treatment (12 months), progression, unacceptable toxicity, or death.
Number of subjects: 39
Study: 38537483

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study: 38537615

Group type: EXPERIMENTAL
Intervention: Colorimetric ETCO2 detector
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (without ETCO2 detector)
Number of subjects: 50
Study: 38537636

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) plus standard HFrEF treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard HFrEF therapy alone
Number of subjects: 117
Study: 38537676

Group type: EXPERIMENTAL
Intervention: Fesomersen 40 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Fesomersen 80 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Fesomersen 120 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Fesomersen (all doses pooled)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Fesomersen (all doses)
Number of subjects: 308
Study: 38537773

Group type: EXPERIMENTAL
Intervention: OH2 oncolytic viral therapy derived from herpes simplex virus 2 (HSV-2)
Number of subjects: 0
Study: 38537780

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 360

Group type: COMPARATOR
Intervention: Apixaban 5 mg twice daily
Number of subjects: 360
Study: 38537903

Group type: EXPERIMENTAL
Intervention: Single-session, self-guided online acceptance-based workshop targeting food cravings
Number of subjects: 74

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 74
Study: 38537919

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study: 38537918

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study: 38538037

Group type: EXPERIMENTAL
Intervention: Active case detection with molecular (ACDm) testing by high volume quantitative PCR (qPCR)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Passive case detection with molecular testing (PCDm)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard passive case detection (PCD) using rapid diagnostics tests (RDTs)
Number of subjects: 600
Study: 38538057

Group type: EXPERIMENTAL
Intervention: Rescue intracranial stenting (RIS) + best medical treatment (BMT)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 346
Study: 38538093

Group type: EXPERIMENTAL
Intervention: SNK01 in combination with gemcitabine/carboplatin (n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SNK01 in combination with cetuximab/gemcitabine/carboplatin (n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SNK01
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination group (SNK01 + chemotherapy/cetuximab)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study: 38538160

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (cohort 1C)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Long-acting rilpivirine (cohort 1R)
Number of subjects: 55
Study: 38538161

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir or rilpivirine injections
Number of subjects: 55
Study: 38538174

Group type: EXPERIMENTAL
Intervention: Microvascular resistance reserve (MRR)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction (CMD) defined by MRR ≤3.0
Number of subjects: 547
Study: 38538200

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated devices (PCDs)
Number of subjects: 259137

Group type: COMPARATOR
Intervention: Control (no PCDs)
Number of subjects: 259137
Study: 38538225

Group type: EXPERIMENTAL
Intervention: Prolonged continuous theta burst stimulation (pcTBS) targeting the primary motor cortex (M1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prolonged continuous theta burst stimulation (pcTBS) targeting the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 42
Study: 38538559

Group type: EXPERIMENTAL
Intervention: Plasma donor-derived cell-free DNA (dd-cfDNA) measured by the Prospera test (Natera Inc)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gene expression in EMBs assessed by Molecular Microscope Diagnostic System
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison with kidney transplant biopsies (Trifecta-Kidney study)
Number of subjects: 70
Study: 38538574

Group type: EXPERIMENTAL
Intervention: Nivolumab plus capecitabine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 45

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 45
Study: 38538820

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study: 38538861

Group type: EXPERIMENTAL
Intervention: Consolidative radiotherapy (RT)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Conventional immunochemotherapy (R-CHOEP) without RT
Number of subjects: 261
Study: 38538867

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccine encoding 20 shared neoantigens derived from selected common oncogenic driver mutations, combined with immune checkpoint inhibitors ipilimumab and nivolumab.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccine regimen (ChAd68 and samRNA) combined with immune checkpoint inhibitors.
Number of subjects: 19
Study: 38539083

Group type: EXPERIMENTAL
Intervention: LEAF intervention facilitated remotely via the web (N = 200)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: LEAF intervention self-guided online (N = 200)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Emotion reporting control (N = 100)
Number of subjects: 500
Study: 38539250

Group type: EXPERIMENTAL
Intervention: AR home-based therapeutic gait-and-balance exergaming intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 24
Study: 38539415

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study: 38539462

Group type: EXPERIMENTAL
Intervention: Composite intervention consisting of non-hormonal pharmacotherapy, digital cognitive behavioral therapy for insomnia (dCBT-I) using Sleepio, self-management strategies via myPatientSpace mobile application, and nomination of an additional support person/partner
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Composite intervention
Number of subjects: 204
Study: 38539914

Group type: EXPERIMENTAL
Intervention: Dietary antioxidants (high tertiles of DAQI)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cosmetic treatment (cavitation peeling and sonophoresis with a commercial capillary repair serum)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lowest tertile of DAQI
Number of subjects: 160
Study: 38540138

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day for 4 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (30 controls)
Number of subjects: 28
Study: 38540555

Group type: EXPERIMENTAL
Intervention: Mood Lifters (ML) program
Number of subjects: 138
Study: 38541769

Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Hand Rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38541803

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38541922

Group type: EXPERIMENTAL
Intervention: Intervention not specified in the abstract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified in the abstract
Number of subjects: 0
Study: 38542033

Group type: EXPERIMENTAL
Intervention: Machine Learning intervention for predicting length of mechanical ventilation
Number of subjects: 0
Study: 38543926

Group type: EXPERIMENTAL
Intervention: Aerosolized Ad5-nCoV (Low-Dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular Ad5-nCoV (Low-Dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular-Aerosolized Ad5-nCoV (Low-Dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38544413

Group type: EXPERIMENTAL
Intervention: GORE VIABAHN Endoprosthesis
Number of subjects: 0
Study: 38544553

Group type: EXPERIMENTAL
Intervention: Plasma exchange with albumin 5% (PE-A5%)
Number of subjects: 10
Study: 38544798

Group type: EXPERIMENTAL
Intervention: Combination treatment (GLP-1 receptor agonist + supervised exercise)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Liraglutide alone
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 38544834

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with chemotherapy plus trastuzumab for breast cancer patients
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES) for both breast and prostate cancer patients
Number of subjects: 550
Study: 38544919

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) including aspirin and clopidogrel
Number of subjects: 188860

Group type: EXPERIMENTAL
Intervention: Class 1 (cardiovascular-kidney-metabolic comorbidities)
Number of subjects: 188860

Group type: EXPERIMENTAL
Intervention: Class 2 (hypertension-dyslipidaemia comorbidities)
Number of subjects: 188860

Group type: COMPARATOR
Intervention: Class 3 (non-specific comorbidities)
Number of subjects: 188860
Study: 38545090

Group type: EXPERIMENTAL
Intervention: BIO101 (350 mg BID)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 38545091

Group type: EXPERIMENTAL
Intervention: Human milk-based fortifier (HMBF)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Bovine milk-based fortifier (BMBF)
Number of subjects: 228
Study: 38545092

Group type: EXPERIMENTAL
Intervention: VBI-S (phospholipid nanoparticles) administered intravenously as boluses of 100 ml, 200 ml, 400 ml, and 800 ml until MAP goal was reached.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VBI-S (phospholipid nanoparticles) administered intravenously.
Number of subjects: 20
Study: 38545723

Group type: EXPERIMENTAL
Intervention: Controlled hypertension group
Number of subjects: 302

Group type: COMPARATOR
Intervention: Non-controlled hypertension group
Number of subjects: 302
Study: 38545762

Group type: EXPERIMENTAL
Intervention: Daily Ecological Momentary Assessments of Pain and Ability to Work
Number of subjects: 0
Study: 38545781

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously monthly or biweekly
Number of subjects: 39
Study: 38546220

Group type: EXPERIMENTAL
Intervention: TILT-123 (igrelimogene litadenorepvec) administered intravenously and intratumorally
Number of subjects: 20
Study: 38546375

Group type: EXPERIMENTAL
Intervention: Orelabrutinib, dosage and duration not available
Number of subjects: 0
Study: 38546421

Group type: EXPERIMENTAL
Intervention: Brief Simha Kriya Breathing Practice
Number of subjects: 0
Study: 38546428

Group type: EXPERIMENTAL
Intervention: Low-Frequency Electrical Acupoint Stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Frequency Electrical Acupoint Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 0
Study: 38546454

Group type: EXPERIMENTAL
Intervention: Increased nitrate intake from beetroot juice over 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 38546529

Group type: EXPERIMENTAL
Intervention: Intervention not specified; control group not specified.
Number of subjects: 0
Study: 38546554

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Pain psychoeducation (ED)
Number of subjects: 262
Study: 38546621

Group type: EXPERIMENTAL
Intervention: In-person group parenting program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehealth parenting program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed online parenting program
Number of subjects: 0
Study: 38546622

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study: 38546803

Group type: EXPERIMENTAL
Intervention: Crisaborole QD (once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 38546821

Group type: EXPERIMENTAL
Intervention: 5-day fasting-mimicking diet (FMD) programme, monthly cycles as an adjunct to regular care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular care only
Number of subjects: 100
Study: 38546822

Group type: EXPERIMENTAL
Intervention: Active cervical tVNS
Number of subjects: 145

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 145
Study: 38546829

Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film (SL-APO)
Number of subjects: 496
Study: 38546897

Group type: EXPERIMENTAL
Intervention: Surgical side of the thorax (diaphragmatic excursion measures)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surgical side of the thorax (phrenic nerve conduction measures)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-surgical side of the thorax (phrenic nerve conduction measures)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postoperative reduction in posterior diaphragmatic excursion
Number of subjects: 40
Study: 38546944

Group type: EXPERIMENTAL
Intervention: EGFR-Erbitux receptor targeted EnGeneIC Dream Vector with mitoxantrone
Number of subjects: 9
Study: 38546960

Group type: EXPERIMENTAL
Intervention: Zanubrutinib (Bruton tyrosine kinase inhibitor)
Number of subjects: 5
Study: 38547003

Group type: EXPERIMENTAL
Intervention: liso-cel (CAR T cell therapy)
Number of subjects: 184

Group type: COMPARATOR
Intervention: standard of care (SOC)
Number of subjects: 184